| SIN 3 complex |  | 2 | 6 |  | 4 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Histone deacetylase complex subunit SAP18 | SAP18 |  |  | 6 |  |
| CoRESt complex |  |  |  |  |  |
| REST corepressor 1 | RCOR1 | 2 | 2 | 2 | 3 |
| PRC1 complex |  |  |  |  |  |
| E3 ubiquitin-protein ligase RING2 | RNF2/RING1B | 1 | 4 | 2 | 0 |
| MLL1/MLL complex |  |  |  |  |  |
| Isoform 14P-18B of Histone-lysine N-methyltransferase MLL | MLL/KMT2A | 0 | 2 | 2 | 0 |
| WD repeat-containing protein 5 | WDR5 | 2 | 4 | 6 | 0 |
| Isoform 2 of Menin | MEN1 | 3 | 0 | 2 | 1 |


| CHD4/NuRD complex |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | CHD4 | 3 | 21 | 6 | 0 |
| Isoform 2 of Lysine-specific histone demethylase 1A | KDM1A/LSD1 ${ }^{\text {a }}$ | 3 | 5 | 6 | 8 |
| Histone deacetylase 1 | HDAC1 ${ }^{\text {b }}$ | 3 | 3 | 2 | 2 |
| Histone deacetylase 2 | HDAC2 ${ }^{\text {b }}$ | 9 | 6 | 7 | 10 |
| Histone-binding protein RBBP4 | RBBP4 ${ }^{\text {b }}$ | 10 | 7 | 6 | 7 |
| Histone-binding protein RBBP7 | RBBP7 ${ }^{\text {b }}$ | 2 | 1 | 0 | 3 |
| Transcriptional repressor p66-alpha | GATAD2A | 6 | 2 | 0 | 4 |
| Metastasis-associated protein MTA2 | MTA2 | 8 | 1 | 2 | 6 |
| SWI/SNF complex BAF |  |  |  |  |  |
| SMARCA4 isoform | SMARCA4/BRG1 | 6 | 13 | 10 | 0 |
| AT-rich interactive domain-containing protein 1A | ARID1A/BAF250 | 2 | 6 | 1 | 0 |
| SWI/SNF complex subunit SMARCC1 | SMARCC1/BAF155 ${ }^{\circ}$ | 6 | 11 | 8 | 0 |
| SWI/SNF complex subunit SMARCC2 | SMARCC2/BAF170 | 2 | 2 | 0 | 0 |
| Isoform 2 of SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 1 | SMARCD1/BAF60ac | 2 | 0 | 0 | 4 |
| Isoform 2 of SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 3 | SMARCD3/BAF60c ${ }^{\text {c }}$ | 7 | 2 | 0 | 9 |
| Isoform 2 of SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1 | SMARCE1/BAF57 ${ }^{\text {c }}$ | 4 | 2 | 0 | 5 |
| Actin-like protein 6A | ACTL6A/BAF53a ${ }^{\text {c }}$ | 7 | 7 | 0 | 0 |
| SWI/SNF complex PBAF |  |  |  |  |  |
| Isoform 2 of Protein polybromo-1 | PBRM1/BAF180 | 0 | 5 | 3 | 0 |
| ISWI complex NURF |  |  |  |  |  |
| Uncharacterized protein GN=SMARCA1 | SMARCA1/SNF2L | 0 | 9 | 6 | 0 |
| ISWI complex ACF |  |  |  |  |  |
| SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5 | SMARCA5/SNF2H ${ }^{\text {d }}$ | 22 | 30 | 26 | 0 |
| Isoform 2 of Bromodomain adjacent to zinc finger domain protein 1A | BAZ1A/ACF1 | 0 | 5 | 2 | 0 |
| ISWI complex WICH |  |  |  |  |  |
| Isoform 2 of Tyrosine-protein kinase BAZ1B | BAZ1B/WSTF ${ }^{\text {e }}$ | 4 | 8 | 13 | 0 |
| ISWI complex NoRC |  |  |  |  |  |
| Isoform 1 of Bromodomain adjacent to zinc finger domain protein 2A | BAZ2A/Tip5 | 5 | 5 | 1 | 0 |

${ }^{\text {a }}$ also associates with the CoREST complex
are also associated with RCOR1 or SAP18 in the SIN3 or CoREST complex
${ }^{\text {c }}$ are also associated with BAF180 to form the PBAF complex
${ }^{\text {d }}$ SNF2H also associates with BAZ2A to form the NoRC complex
${ }^{\text {e }}$ also associates with BRG1 to form the WINAC complex

| Transcription factor A, mitochondrial | TFAM | 1 | 10 | 5 | 2 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| C-terminal-binding protein 1 | CTBP1 | 9 | 4 | 7 | 8 |
| Isoform 2 of C-terminal-binding protein 2 | CTBP2 | 6 | 2 | 5 | 7 |
| Zinc finger protein 326 | ZNF326 | 6 | 12 | 8 | 13 |
| Zinc finger protein 148 | ZNF148 | 4 | 12 | 5 | 2 |
| Isoform 2 of Zinc finger protein 384 | ZNF384 | 3 | 4 | 1 | 5 |
| Zinc finger protein 638 | ZNF638 | 3 | 14 | 0 | 0 |
| Zinc finger protein 281 | ZNF281 | 2 | 3 | 1 | 0 |
| Prospero homeobox protein 1 | PROX1 | 21 | 4 | 7 | 14 |
| Nuclear receptor coactivator 5 | NCOA5 | 14 | 6 | 6 | 11 |
| Isoform UBF2 of Nucleolar transcription factor 1 | UBTF | 18 | 7 | 4 | 5 |
| Isoform 2 of Transcription factor AP-2-beta | TFAP2B | 15 | 4 | 8 | 6 |
| Isoform 2 of DNA-binding protein SATB1 | SATB1 | 7 | 3 | 2 | 4 |
| Putative uncharacterized protein SATB2 | SATB2 | 12 | 3 | 2 | 4 |
| Isoform B of Methyl-CpG-binding protein 2 | MECP2 | 3 | 4 | 2 | 8 |
| Isoform 2 of Nuclear transcription factor Y subunit gamma | NFYC | 4 | 3 | 4 | 4 |
| Transcriptional repressor CTCF | CTCF | 4 | 6 | 2 | 2 |
| SAFB-like transcription modulator | SLTM | 2 | 14 | 4 | 0 |
| Transcription factor AP-1 | JUN | 4 | 8 | 3 | 0 |
| Transcription factor MafG | MAFG | 1 | 8 | 2 | 2 |
| Zinc finger RNA-binding protein | ZFR | 4 | 9 | 6 | 0 |
| Isoform 2 of Homeobox-containing protein 1 | HMBOX1 | 3 | 3 | 1 | 5 |
| Nuclear factor interleukin-3-regulated protein | NFIL3 | 8 | 0 | 2 | 2 |
| Zinc finger protein ubi-d4 | DPF2 | 2 | 2 | 0 | 6 |
| Transcriptional enhancer factor TEF-1 | TEAD1 | 0 | 3 | 2 | 3 |
| Isoform 2 of Chromodomain-helicase-DNA-binding protein 1 | CHD1 | 2 | 6 | 4 | 0 |
| Chromodomain-helicase-DNA-binding protein 7 | CHD7 | 13 | 35 | 0 | 0 |
| Isoform 2 of Protein ELYS | AHCTF1 | 0 | 27 | 13 | 0 |
| MHC class II regulatory factor RFX1 | RFX1 | 1 | 12 | 10 | 0 |
| Isoform 1 of RNA-binding protein 14 | RBM14 | 0 | 0 | 11 | 11 |
| Pinin | PNN | 2 | 18 | 0 | 0 |
| Isoform 2 of Zinc finger homeobox protein 4 | ZFHX4 | 0 | 18 | 5 | 0 |
| MICOS complex subunit MIC19 | CHCHD3 | 0 | 8 | 6 | 0 |
| Helix-loop-helix transcription factor 4 isoform c | TCF12 | 0 | 0 | 3 | 10 |
| Actin-like protein 6A | ACTL6A | 7 | 7 | 0 | 0 |
| Cyclic AMP-dependent transcription factor ATF-3 | ATF3 | 0 | 6 | 3 | 1 |
| Isoform 1 of Core-binding factor subunit beta | CBFB | 0 | 0 | 6 | 3 |
| Isoform 2 of Ubinuclein-1 | UBN1 | 1 | 6 | 6 | 0 |
| Activity-dependent neuroprotector homeobox protein | ADNP | 1 | 7 | 4 | 0 |
| Isoform PTX2C of Pituitary homeobox 2 | PITX2 | 0 | 3 | 4 | 0 |
| Isoform 2 of ATP-binding cassette sub-family F member 1 | ABCF1 | 4 | 0 | 0 | 3 |
| Transcription factor AP-4 | TFAP4 | 1 | 4 | 3 | 0 |
| Isoform AML-1G of Runt-related transcription factor 1 | RUNX1 | 2 | 6 | 10 | 6 |
| Isoform 3 of Runt-related transcription factor 2 | RUNX2 | 0 | 1 | 4 | 2 |
| Myoblast determination protein 1 | MYOD1 | 1 | 4 | 4 | 0 |
| Myogenin | MYOG | 2 | 5 | 4 | 0 |
| Zinc finger E-box-binding homeobox 1 | ZEB1 | 0 | 5 | 4 | 0 |
| Zinc finger E-box-binding homeobox 2 | ZEB2 | 2 | 4 | 1 | 0 |
| Isoform 1 of Suppressor of fused homolog | SUFU | 0 | 0 | 3 | 5 |
| Isoform 1 of General transcription factor 3C polypeptide 5 | GTF3C5 | 1 | 0 | 3 | 4 |
| Homeobox protein SIX1 | SIX1 | 0 | 4 | 3 | 0 |
| Zinc finger and BTB domain-containing protein 7A | ZBTB7A | 2 | 0 | 0 | 3 |
| CREB-binding protein | CREBBP | 0 | 4 | 4 | 0 |
| Teashirt homolog 3 | TSHZ3 | 0 | 2 | 5 | 0 |
| Basonuclin 2 | BNC2 | 0 | 3 |  | 0 |
| Nascent polypeptide-associated complex subunit alpha | NACA | 0 | 3 | 2 | 0 |


| Isoform 2 of Protein CBFA2T2 | CBFA2T2 | 2 | 0 | 0 | 2 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Isoform 1 of Core histone Facro-H2A.1 | CIIAFY | 6 | 7 | 6 | 3 |
| Histone H2A.Z | H2AFY | H2AFZ | 3 | 3 | 3 |
| Histone H2A Aype 2-B | HITT2H2AB | 4 | 3 | 2 | 1 |
| Isoform Short of Protein HIRA | HIRA | 14 | 6 | 3 | 3 |
| Histone chaperone ASF1B | ASF1B | 0 | 2 | 2 | 0 |

## Enzyme: 31 Proteins

| Isoform Beta of Zinc finger protein RFP | TRIM27 | 4 | 1 | 3 | 3 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| E3 ubiquitin-protein ligase UBR5 | UBR5 | 0 | 7 | 6 | 0 |
| NAD-dependent deacetylase sittuin-1 | SIRT1 | 8 | 0 | 3 | 1 |
| CAD protein | CAD | 5 | 20 | 51 | 0 |
| Serine/threonine-protein phosphatase 2 A catalytic subunit beta isoform | PPP2CB | 2 | 3 | 9 | 0 |
| Isoform 2 of Serine/threonine-protein phosphatase 6 regulatory subunit 3 | PPP6R3 | 8 | 0 | 2 | 0 |
| Isoform 1 of Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A | ANKRD28 | 6 | 0 | 2 | 0 |
| Aurora kinase B | AURKB | 0 | 2 | 3 | 0 |
| Casein kinase II subunit alpha | CSNK2A1 | 2 | 0 | 2 | 0 |
| Serine/threonine-protein phosphatase 2 A 55 kDa regulatory subunit B alpha isoform | PPP2R2A | 12 | 5 | 13 | 7 |
| Probable ATP-dependent RNA helicase DDX41 | DDX41 | 4 | 3 | 3 | 4 |
| Probable ATP-dependent RNA helicase DDX27 | DDX27 | 5 | 3 | 0 | 3 |
| ATP-dependent RNA helicase DDX1 | DDX1 | 0 | 1 | 7 | 6 |
| ATP-dependent RNA helicase DDX50 | DDX50 | 3 | 1 | 1 | 5 |
| Nucleolar RNA helicase 2 | DDX21 | 16 | 6 | 0 | 0 |
| Calcineurin-binding protein cabin-1 | CABIN1 | 5 | 10 | 4 | 0 |
| Inactive serine/threonine-protein kinase VRK3 | VRK3 | 1 | 3 | 2 | 5 |
| Isoform 2 of $5^{\prime} 3^{\prime}{ }^{\prime}$ exoribonuclease 2 | XRN2 | 2 | 1 | 2 | 3 |
| Superkiller viralicidic activity 2 -like 2 | SKIV2L2 | 2 | 2 | 5 | 0 |
| DNA-directed RNA polymerases I, II, and IIII subunit RPABC1 | POLR2E | 0 | 3 | 5 | 1 |
| DNA-directed RNA polymerase | POLR2B | 0 | 9 | 14 | 0 |
| DNA ligase 3 | LIG3 | 3 | 9 | 0 | 0 |
| Isoform 3 of Apoptosis-inducing factor 1 | AIFM1 | 2 | 1 | 7 | 5 |
| DNA-directed RNA polymerases I, II, and III subunit RPABC1 | POLR2E | 0 | 3 | 5 | 1 |
| N -acetyltransferase 10 | NAT10 | 3 | 3 | 0 | 0 |
| Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3 B | АРОВЕСЗВ | 0 | 5 | 2 | 0 |
| Transcription termination factor 2 | TTF2 | 5 | 2 | 0 | 0 |
| ATPase family AAA domain-containing protein 2 | ATAD2 | 2 | 3 | 0 | 0 |
| Isoform Complexed of ArginyltRNA synthetase, cytoplasmic | RARS | 0 | 0 | 4 | 10 |
| Peptidyl-proly cis-trans isomerase-like 1 | PPIL1 | 3 | 3 | 2 | 0 |
| Peptidyl-proly cis-trans isomerase H | PPIH | 0 | 2 | 3 | 0 |


| Proliferating cell nuclear antigen | PCNA | 2 | 7 | 10 | 0 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Isoform Beta-1 of DNA topoisomerase 2-beta | TOP2B | 13 | 21 | 16 | 0 |
| Replication protein A 70 kDa DNA-binding subunit | RPA1 | 23 | 16 | 15 | 12 |
| Isoform Short of DNA topoisomerase 3-alpha | TOP3A | 11 | 13 | 8 | 7 |
| DNA replication licensing factor MCM5 | МСМ5 | 7 | 5 | 3 | 17 |
| Replication protein A 32 kDa subunit | RPA2 | 2 | 5 | 5 | 0 |
| DNA repair protein XRCC1 | XRCC1 | 0 | 6 | 2 | 3 |
| Isoform 2 of DNA-dependent protein kinase catalytic subunit | PRKDC | 63 | 114 | 109 | 0 |
| Structural maintenance of chromosomes protein 5 | SMC5 | 1 | 15 | 12 | 0 |
| Structural maintenance of chromosomes protein 1A | SMC1A | 1 | 13 | 3 | 0 |
| Isoform 2 of Tumor suppressor p53-binding protein 1 | TP53BP1 | 0 | 10 | 12 | 0 |
| Melanoma-associated antigen G 1 | NDNL2 | 0 | 9 | 4 | 0 |
| Replication factor C subunit 4 | RFC4 | 1 | 5 | 3 | 0 |
| DNA mismatch repair protein Msh2 | MSH2 | 2 | 4 | 0 | 0 |
| RecQ-mediated genome instabiily protein 2 | RMI2 | 2 | 2 | 0 | 0 |
| Bloom syndrome protein | BLM | 2 | 13 | 8 | 0 |

Cell Cycle: 9

| E3 SUMO-protein ligase RanBP2 | RANBP2 | 4 | 76 | 39 | 0 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Cell division protein kinase 4 | CDK4 | 0 | 6 | 7 | 0 |
| Probable 285 rRNA (cytosine(4447)-C(5))-methyltransferase | NOP2 | 2 | 6 | 2 | 4 |
| Isoform 2 of Mediator of DNA damage checkpoint protein 1 | MDC1 | 7 | 19 | 14 | 0 |
| Isoform 2 of Pogo transposable element with ZNF domain | POGz | 2 | 8 | 10 | 0 |
| MK167 FHA domain-interacting nucleolar phosphoprotein | MK167 | 2 | 35 | 0 | 0 |
| Prohibitin | PHB | 1 | 2 | 4 | 0 |
| Borealin | CDCA8 | 0 | 2 | 2 | 0 |
| Isoform 2 of Protein KIAA1967 | KIAA1967 | 15 | 7 | 6 | 0 |

## Transporter: 7

| Transporter: 7 | Nuclear RNA export factor 1 | NXF1 | 5 | 16 | 11 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Importin subunit alpha-1 | KPNA1 | 3 | 2 | 7 | 5 |
| Exportin-1 | XP1 | 1 | 4 | 4 | 4 |
| THO complex subunit 4 | THOC4 | 2 | 3 | 4 | 0 |
| Importin subunit alpha-3 | KPNA3 | 3 | 1 | 3 | 4 |
| GTP-biding nuclear protin Ran | RAN | 0 | 6 | 11 | 0 |
| Isoform 2 of Transportin-1 | TNPO1 | 4 | 0 | 1 | 3 |



| Nucleolar GTP-binding protein 1 | GTPBP4 | 0 | 2 | 0 | 4 |
| ---: | :---: | :---: | :---: | :---: | :---: |
| DNA-directed RNA polymerase II subunit RPB3 | POLR2C | 0 | 6 | 4 | 0 |
| Protein Wiz | WIZ | 2 | 3 | 0 | 0 |
| PHD finger protein 14 | PHF14 | 1 | 4 | 2 | 0 |
| Glutamate-rich WD repeat-containing protein 1 | GRWD1 | 1 | 0 | 3 | 2 |
| Unc-84 homolog A (C. elegans) | UNC84A | 2 | 4 | 0 | 0 |
| AT-hook DNA-binding motif-containing protein 1 | AHDC1 | 0 | 3 | 3 |  |
| AIMP1 | 0 | 2 | 2 | 0 |  |
| Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 | COPS4 | 3 | 0 | 3 | 0 |
| COP9 signalosome complex subunit 4 | NSMCE4A | 0 | 0 | 2 | 3 |
| Isoform 1 of Non-structural maintenance of chromosomes element 4 homolog A | WDR18 | 2 | 0 | 2 | 0 |
| WD repeat-containing protein 18 | RFC1 | 0 | 3 | 2 | 0 |
| Isoform 2 of Replication factor C subunit 1 | EIF6 | 0 | 2 | 3 | 0 |
| Eukaryotic translation initiation factor 6 |  |  |  |  |  |


| Transcriptional Regulation: | 63 |
| :---: | :---: |
| Enzyme: | 31 |
| Chromatin Modifying complexes | 27 |
| DNA Replication/Repair: | 16 |
| Cell Cycle: | 9 |
| Transporter: | 7 |
| Other: | Total |

Proteins with exclusively non nuclear localisation: 29
Enzyme: 18

| cAMP-dependent protein kinase type l-alpha regulatory subunit | PRKAR1A | 3 | 5 | 3 | 4 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B delta isoform | PPP2R2D | 2 | 0 | 4 | 0 |
| Glutaminyl-tRNA synthetase | QARS | 0 | 4 | 3 | 13 |
| Bifunctional aminoacyl-tRNA synthetase | EPRS | 3 | 9 | 5 | 0 |
| Isoleucyl-tRNA synthetase, cytoplasmic | IARS | 3 | 10 | 7 | 0 |
| Methionyl-tRNA synthetase, cytoplasmic | MARS | 1 | 2 | 5 | 8 |
| Chromosome 6 open reading frame 150 | C6orf150 | 9 | 2 | 1 | 2 |
| Fatty acid synthase | FASN | 0 | 8 | 20 | 0 |
| Leucyl-tRNA synthetase, cytoplasmic | LARS | 1 | 10 | 13 | 0 |
| Isoform Mitochondrial of Lysyl-tRNA synthetase | KARS | 1 | 1 | 2 | 6 |
| Multifunctional protein ADE2 | PAICS | 2 | 1 | 6 | 1 |
| Isoform 2 of ATPase family AAA domain-containing protein 2B | ATAD2B | 0 | 6 | 2 | 0 |
| Hydroxymethylglutaryl-CoA synthase, cytoplasmic | HMGCS1 | 1 | 3 | 3 | 1 |
| Vesicle-fusing ATPase | NSF | 0 | 0 | 3 | 2 |
| L-lactate dehydrogenase | LDHA | 0 | 2 | 4 | 0 |
| Isoform 2 of Putative ATP-dependent RNA helicase DHX30 | DHX30 | 7 | 5 | 13 | 0 |
| Isoform 2 of Probable ubiquitin carboxyl-terminal hydrolase FAF-X | USP9X | 13 | 9 | 46 | 0 |
| Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 | RPN1 | 3 | 1 | 4 | 2 |

Other: 11

| Prolow-density lipoprotein receptor-related protein 1 | LRP1 | 0 | 34 | 33 | 2 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Charged multivesicular body protein 4b | CHMP4B | 2 | 5 | 5 | 0 |
| DnaJ homolog subfamily A member 1 | DNAJA1 | 8 | 5 | 10 | 5 |
| Programmed cell death 6-interacting protein | PDCD6IP | 2 | 4 | 3 | 2 |
| BAG family molecular chaperone regulator 2 | BAG2 | 0 | 3 | 8 | 2 |
| Isoform Short of 14-3-3 protein beta/alpha | YWHAB | 2 | 6 | 8 | 0 |
| DnaJ homolog subfamily C member 9 | DNAJC9 | 1 | 9 | 10 | 0 |
| Isoform 2 of Structural maintenance of chromosomes flexible hinge domain-containing protein 1 | SMCHD1 | 0 | 3 | 4 | 0 |
| Ribonuclease inhibitor | RNH1 | 1 | 1 | 3 | 3 |
| 14-3-3 protein gamma | YWHAG | 1 | 3 | 5 | 0 |
| Elongation factor 1-beta | EEF1B2 | 0 | 2 | 2 | 0 |


| Enzyme: | 18 |
| :---: | :--- |
| Other: | 11 |
| Total: | 29 |

Supplementary Table S2: Custom siRNA Library

| RefSeq Accession | $\begin{array}{\|l\|} \hline \begin{array}{l} \text { Gene } \\ \text { Symbol } \end{array} \\ \hline \end{array}$ | Full Gene Name | siRNA ID | Exon(s) | Sense siRNA Sequence | Antisense siRNA Sequence |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| NM_006015 | ARID1A | AT rich interactive domain 1 A (SWL-like) | s15784 | 11,11 | GGAAACCUCUGGACCUCUAAt | UAGAGGUCCAGAGGUUUCCTa |
| NM_006015 | ARIDA | AT rich interactive domain 1 A (SWW-like) | s15785 | 20,20 | cGgUAUCACCGUUGAUGAAtt | UUCAUCAACGGUGAUACC |
| NM_006015 | ARIDIA | AT rich interactive domain 1 A (SWW-like) | s15786 | 9,9 | GGACAAGGGAUUAAUAGUAAt | UACUAUUAAUCCCUUGUCCat |
| NM_032408 | BAZ1B | bromodomain adjacent toz zinc finger domain, 1B | s17208 | Not Determined | GAUCGAAACCAUAAUAGAUIt | AUCUAUUAUGGUUUCGAUCIg |
| NM_032408 | BAZ1B | bromodomain adjacent toz zinc finger domain, 1B | s17209 | Not Determined | ccuucguagubaucucauut | AAUGAGAUCACUACGAAGGaa |
| NM_032408 | BAZ1B | bromodomain ajjacent toz zinc finger domain, 1B | s17210 | Not Determined | cCUCAUUGCAUACUACAAAIt | UUUGUAGUAUGCAAUGAGG |
| NM_013449 | BAZ2A | bromodomain adjacent to zinc finger domain, 2A | s22056 | 24 | GAGAUAUCAUAUGAGAUCAIt | UGAUCUCAUAUGAUAUCUCTg |
| NM_013449 | BAZ2A | bromodomain adjacent to zinc finger domain, 2A | s22057 | 28 | GCAUCAUCAAAAAUCCUAUTt | AUAGGAUUUUUGAUGAUGCgc |
| NM_013449 | BAZ2A | bromodomain adjacent to zinc finger domain, 2 A | s22058 | 20 | CAAGCACUCUGGUUUAACAIt | UGUUAAACCAGAGUGCUUGag |
| NM_000057 | BLM | Bloom syndrome, RecQ helicase-like | s1997 | 21 | CCCACUACUUUGCAAGUAAtt | UUACUUGCAAAGUAGUGGGaa |
| NM_000057 | BLM | Bioom syndrome, RecQ helicase-like | s1998 | 5 | GGAUGUUCUUAGCACAUCAAt | UGAUGUGCUAAGAACAUCCIC |
| NM_000057 | BLM | Bloom syndrome, RecQ helicase-like | s1999 | 22 | GAUAUCUUCCAAAACGAAAtt | UUUCGUUUUGGAAGAUAUCt |
| NM_012295 | CABIN1 | calcineurin binding protein 1 | s24000 | 9 | GGAUUGAUUUGUCGGACUAIt | UAGUCCGACAAAUCAAUCCIt |
| NM_012295 | CABIN1 | calcineurin binding protein 1 | s24001 | 7 | GGAUUGCCGGUACAGCAAAtt | UUUGCUGUACCGGCAAUCCIt |
| NM_012295 | CABIN1 | calcineurin binding protein 1 | s2402 | 19 | GCGAUUCUAUGUGCGAGUAIt | UACUCGCACAUAGAAUCGCag |
| NM_001270 | CHD1 | chromodomain helicase DNA binding protein 1 | s2974 | 18 | GGUGAAUAUUUAUCGUCUAAt | UAGACGAUAAAUAUUCACCIg |
| NM_001270 | CHD1 | chromodomain helicase DNA binding protein 1 | s2975 | 3 | CAUCAAGCCUCAUCUAAUAIt | UAUUAGAUGAGGCUUGAUGIt |
| NM_001270 | CHD1 | chromodomain helicase DNA binding protein 1 | s2976 | 26 | GGGUCCAACAUUCCGAAUAAt | UAUUCGGAAUGUUGGACCCIt |
| NM_001273 | CHD4 | chromodomain helicase DNA binding protein 4 | s2983 | 12 | CUAUCGCUAUGGGAUAAAAAT | UUUUAUCCCAUAGCGAUAGaa |
| NM_001273 | CHD4 | chromodomain helicase DNA binding protein 4 | s2984 | 29 | GCAAUUAUGCGAUAUGGUAAt | UACCAUAUCGCAUAAUUGCat |
| NM_006015 | CHD4 | chromodomain helicase DNA binding protein 4 | s2985 | 20 | CACUCGAAAUUUUGAAGCAIt | UGCUUCAAAAUUUCGAGUGag |
| NM_006015 | CHD7 | chromodomain helicase DNA binding protein 7 | s31140 | 15 | CUAACGUACCUAACCUAUUTI | AAUAGGUUAGGUACGUUAGct |
| NM_006015 | CHD7 | chromodomain helicase DNA binding protein 7 | s31141 | 31 | GGAUGACGAUAAGUCGGAAtt | UUCCGACUUAUCGUCAUCCIC |
| NM_032408 | CHD7 | chromodomain helicase DNA binding protein 7 | s31142 | 2 | GGGAUUAGUUAACAAUACAIt | UGUAUUGUUAACUAAUCCCIg |
| NM_032408 | cops4 | COP9 constitutive photomorphogenic homolog subunit 4 (Arabidopsis) | s27533 | 4 | GCAUCUUGCAUCUAUAUAUUT | AUAUAUAGAUGCAAGAUGCtg |
| NM_032408 | cops4 | COP9 constitutive photomorphogenic homolog subunit 4 Arabidiopsis) | s27534 | 3 | CUUCCUAACUUGCCUGAUAAt | UAUCAGGCAAGUUAGGAAGat |
| NM_013449 | COPS4 | cop9 constitutive photomorphogenic homolog subunit 4 Arabidopsis) | s27535 | 5 | cGAGCAUCGUUGCUUCAGAtt | UCUGAAGCAACGAUGCUCGat |
| NM_013449 | CTBP1 | C-terminal binding protein 1 | s3698 | 8,7 | CUCUGAAGGAUGCACCCAAAt | UUGGGUGCAUCCUUCAGAGgg |
| NM_013449 | CTBP1 | C-terminal binding protein 1 | s3699 | 4,3 | GGCAGUGGUUUUGACAACAIt | UGUUGUCAAAACCACUGCCaa |
| NM_000057 | CTBP1 | C-terminal binding protein 1 | s3700 | 10,9 | GUUUGUGACUGUAACCAUUTI | AAUGGUUACAGUCACAAACat |
| NM_000057 | CTBP2 | C-terminal binding protein 2 | s3701 | 11,11,9 | GgAAAAUCACAUUACUACAIt | UGUAGUAAUGUGAUUUUCCTa |
| NM_000057 | CTBP2 | C-terminal binding protein 2 | s3702 | 5,5,3 | GGAAUUGCCGUGUGCAACAIt | UGUUGCACACGGCAAUUCCga |
| NM_012295 | CTBP2 | C-terminal binding protein 2 | s56075 | Not Determined | CAUCAAUGACUUUACCAUAIt | UAUGGUAAAGUCAUUGAUGag |
| NM_012295 | CTCF | CCCTC-binding factor (Zinc finger protein) | s20966 | 6 | CAUUCGCUCUCAUACUGGAAt | UCCAGUAUGAGAGCGAAUGG |
| NM_012295 | CTCF | CCCTC-binding factor (Zinc finger protein) | s20967 | 3 | GGACGAUACCCAGAUUAUAAt | UAUAAUCUGGGUAUCGUCCac |
| NM_001270 | CTCF | CCCTC-binding factor (zinc finger protein) | s20968 | 4 | GCUUUGCAGUUACACGUGUIt | ACACGUGUAACUGCAAAGCIC |
| NM_001270 | DDX1 | DEAD (Asp-Glu-Al-Asp) box polypeptide 1 | s4001 | 3 | GAAUCUAUCCCAUUGAUCUIt | AGAUCAAUGGGAUAGAUUCag |
| NM_001270 | DDX1 | DEAD (Asp-GIu-Ala-Asp) box polypeptide 1 | s4002 | 10 | GAUGUUACCUGGAUAUAGAIt | UCUAUAUCCAGGUAACAUCca |
| NM_001273 | DDX1 | DEAD (Asp-Glu-Al-Asp) box polypeptide 1 | s4003 | 12 | GGCACCGGAUGGUUACAUUIt | AAUGUAACCAUCCGGUGCCtt |
| NM_001273 | DDX21 | DEAD (Asp-GIu-Ala-Asp) box polypepitide 21 | s17563 | 14 | CUACCGCAUCAGUAACAGAtt | UCUGUUACUGAUGCGGUAGgt |
| NM_006015 | DDX21 | DEAD (Asp-Glu-Ala-Asp) box polypepitide 21 | s17564 | 5 | GGAGGUCAAUUUGAACGCAIt | UGCGUUCAAAUUGACCUCCat |
| NM_006015 | DDX21 | DEAD (Asp-Glu-Ala-Asp) box polypepitide 21 | s17565 | 10 | GGAAUUAAGUUCAAACGAAtt | UUCGUUUGAACUUAAUUCCcg |
| NM_006015 | DDX27 | DEAD (Asp-GIu-Ala-Asp) box polypepitide 27 | s31194 | Not Determined | GCAUCUCAGUACGAUGAAAAt | UUUCAUCGUACUGAGAUGCat |
| NM_032408 | DDX27 | DEAD (Asp-GIu-Ala-Asp) box polypepitide 27 | s31196 | Not Determined | GCAGAUACACUCAAAGUAAtt | UUACUUUGAGUGUAUCUGCIt |
| NM_032408 | DDX27 | DEAD (Asp-GIu-Ala-Asp) box polypepitide 27 | s445946 | Not Determined | GAAAGAAAAGGAAAACAGAIt | UCUGUUUUCCUUUUCUUUCga |
| NM_032408 | DDX41 | DEAD (Asp-GIu-Ala-Asp) box polypepitide 41 | 528120 | 8 | GGAACAAGAGAGAGGUUAAt | UAACCUCUUCUCUUGUUCCag |
| NM_013449 | DDX41 | DEAD (Asp-Glu-Ala-Asp) box polypepitide 41 | s28121 | 5 | GGCUAAGGGCAUUACGUAUIt | AUACGUAAUGCCCUUAGCCat |
| NM_013449 | DDX41 | DEAD (Asp-Glu-Ala-Asp) box polypepitide 41 | s 224203 | 8 | GCCGUGACAUGAUAGGCAUTt | AUGCCUAUCAUGUCACGGCca |
| NM_013449 | DD×50 | DEAD (Asp-Glu-Ala-Asp) box polypeptide 50 | s35415 | 13 | GCCUAGAGGAAAUACAGGAAt | UCCUGUAUUUCCUCUAGGCtI |
| NM_000057 | DDX50 | DEAD (Asp-GIu-Ala-Asp) box polypepitide 50 | s35416 | 5 | GGUGGAACAUCAUAUCAAAtt | UUUGAUAUGAUGUUCCACCat |
| NM_000057 | DDX50 | DEAD (Asp-GIu-Ala-Asp) box polypepitide 50 | s35417 | 6 | GGAUCUUUCUAAACUGCGAtt | UCGCAGUUUAGAAAGAUCCaa |
| NM_006015 | DH×30 | DEAH (Asp-Glu-Ala-His) box polypeptide 30 | s22643 | Not Determined | GGACCAUAGAUGUUACCGAtt | UCGGUAACAUCUAUGGUCCct |
| NM_006015 | DH×30 | DEAH (Asp-Glu-Ala-His) box polypeptide 30 | s22644 | Not Determined | CUAGGGACCUAUUAAAAGAAT | UCUUUUAAUAGGUCCCUAGaa |
| NM_006015 | DH×30 | DEAH (Asp-GGu-Ala-His) box polypeptide 30 | s22645 | Not Determined | GcaAuguUaucaucacccatt | UGGGUGAUGAUAACAUUGCag |
| NM_032408 | HDAC1 | histone deacetylase 1 | ${ }^{\text {s73 }}$ | 2 | CUAUGGUCUCUACCGAAAAAT | UUUUCGGUAGAGACCAUAGt |
| NM_032408 | HDAC1 | histone deacetylase 1 | 574 | 7 | CCGGUCAUGUCCAAAGUAAAt | UUACUUUGGACAUGACCGGct |
| NM_032408 | HDAC1 | histone deacetylase 1 | s75 | 10 | CCAAUAUGACUAACCAGAAtt | UUCUGGUUAGUCAUAUUGGaa |
| NM_013449 | HDAC2 | histone deacetylase 2 | s6493 | 8 | GGGUUGUUUCAAUCUAACAIt | UGUUAGAUUGAAACAACCCag |
| NM_013449 | HDAC2 | histone deacetylase 2 | s6994 | 7 | GGCAGAUAUUUAAGCCUAUUT | AUAGGCUUAAAUAUCUGCCCa |
| NM_013449 | HDAC2 | histone deacetylase 2 | s6495 | 1 | CUACGACGGUGAUAUUGGAtt | UCCAAUAUCACCGUCGUAGTa |
| NM_000057 | SAP18 | Sin3A-associated protein, 18kDa | s20098 | Not Determined | GAACUGACAAGCUUAGUAAIt | UUACUAAGCUUGUCAGUUCIt |
| NM_000057 | SAP18 | Sin3A-associated protein, 18kDa | s20099 | Not Determined | UCGUUUUUACAGAUGUUAAAt | UUAACAUCUGUAAAAACGAtt |
| NM_000057 | SAP18 | Sin3A-associated protein, 18kDa | s20100 | Not Determined | GAUCUACACUUGGAUGGAUIt | AUCCAUCCAAGUGUAGAUCTg |
| NM_012295 | GATAD2A | GATA zinc finger domain containing 2A | s224320 | Not Determined | cGUUCAGUCCGUCACCCAAtt | UUGGGUGACGGACUGAACGIg |
| NM_012295 | GATAD2A | GATA zinc finger domain containing 2A | s29501 | Not Determined | GCAAAACUCGUGUUGUUGAtt | UCAACAACACGAGUUUUGCIt |
| NM_012295 | GATAD2A | GATA zinc finger domain containing 2A | s29502 | Not Determined | GCGGCAGAGUCAAAUACAAAt | UUGUAUUUGACUCUGCCGCaa |
| NM_001270 | HIRA | HIR histone cell cycle regulation defective homolog A (S. cerevisisie) | s14521 | 23 | cGAAGGGUUUGAAUACCGAtt | UCGGUAUUCAAACCCUUCGIt |
| NM_001270 | HIRA | HIR histone cell cycle regulation defective homolog A (S. cerevisisie) | s14522 | 15 | cGuccasgaucgatcccautt | AUGGGUUCGAUCUUGGACGgg |
| NM_001270 | HIRA | HIR histone cell cycle regulation defective homolog A (S. cerevisisie) | s445947 | Not Determined | GAUAUUUCCUGGACUCUGAIt | UCAGAGUCCAGGAAAUAUCCa |
| NM_001273 | HMBOX1 | homeobox containing 1 | s35926 | Not Determined | gUACUGGAAUGACUAAACAAt | UGUUUAGUCAUUCCAGUACgc |
| NM_001273 | HMBOX1 | homeobox containing 1 | s35927 | Not Determined | gGagaauadugagcgauuatt | UAAUCGCUCAUUAUUCUCCCt |
| NM_006015 | HMBOX1 | homeobox containing 1 | s35928 | Not Determined | ccaugucucauuauacagatt | UCUGUAUAAUGAGACAUGGtt |
| NM_006015 | AOF2 | amine oxidase (flavin containing) domain 2 | 5617 | Not Determined | GGUCUUGGAGGGAAUCCUAAt | UAGGAUUCCCUCCAAGACCIg |
| NM_006015 | AOF2 | amine oxidase (flavin containing) domain 2 | 5618 | Not Determined | GAGCAAGAGUUUAACCGGUIt | ACCGGUUAAACUCUUGCUCTa |
| NM 032408 | AOF2 | amine oxidase (flavin containing) domain 2 | 5619 | Not Determined | CUGCAGUUGUGGUUGGAUAAt | UAUCCAACCACAACUGCAGtg |
| NM_032408 | JUN | jun proto-oncogene | s7658 | 1 | GGCACAGCUUAAACAGAAAtt | UUUCUGUUUAAGCUGUGCCac |
| NM_032408 | JUN | jun proto-oncogene | s7659 | 1 | CCAAGUGCCGAAAAAGGAAAt | UUCCUUUUUCGGCACUUGGag |
| NM_00228 | JUN | jun proto-oncogene | s7660 | 1 | GGAUCAAGGCGGAGAGGAAtt | UUCCUCUCCGCCUUGAUCCgc |
| NM_021174 | KIAA1967 | KIAA1967 | s33736 | 9,9 | cGCUUAUAGUUCGAAGGUAIt | UACCUUCGAACUAUAAGCGgg |
| NM_021174 | KIAA 1967 | KIAA1967 | s33737 | 19,19 | GGCUCUACCUAGAGAACAAAt | UUGUUCUCUAGGUAGAGCCgg |
| NM_021174 | KIAA1967 | KIAA1967 | ¢33738 | 14,14 | GGCUAUAGAGUUUAUAAGAAt | UCUUAUAAACUCUAUAGCCaa |
| NM_004992 | MECP2 | methy 1 CPG binding protein 2 (Rett syndrome) | s8644 | Not Determined | GGAAGCUCCUUGUCAAGAUTt | AUCUUGACAAGGAGCUUCCca |
| NM_004992 | MECP2 | methy CPG binding protein 2 (Rett sydrome) | s8645 | Not Determined | GACAUUGUUUCAUCCUCCAAt | UGGAGGAUGAAACAAUGUCIt |
| NM_004992 | MECP2 | methy CPG b binding protein 2 (Rett syndrome) | s8646 | Not Determined | GCUUCCCGAUUAACUGAAAAT | UUUCAGUUAAUCGGGAAGCt |
| NM_004739 | MTA2 | metastasis associated 1 family, member 2 | s17629 | 13 | GGAUCUACUGGAAGAAGUAIt | UACUUCUUCCAGUAGAUCCaa |
| NM_004739 | MTA2 | metastasis associated 1 family, member 2 | s17630 | 10 | GCAUAGUCCAGUUUUAUUAAt | UAAUAAAACUGGACUAUGCtg |
| NM_004739 | MTA2 | metastasis associated 1 family, member 2 | s17631 | 10 | ccacagaccgauauauucatt | UGAAUAUACCGGUCUGUGGt |
| NM_002479 | MYOG | myogenin (myogenic factor 4) | s9232 | 3 | ACUUAUUUGGAUUUCCUUUUT | AAAGGAAAUCCAAAUAAGUTa |
| NM_02479 | MYOG | myogenin (myogenic factor 4) | s9233 | 3 | CAAGGUCUCCUGUGCUGAAtt | UUCAGCACAGGAGACCUUGgt |
| NM_002479 | MYOG | myogenin (myogenic factor 4) | s9234 | 3 | ccucauccauguadg $u$ Aatt | UAACCUUACAUGGAUGAGGaa |
| NM_020967 | NCOAS | nuclear receptor coactivator 5 | s33688 | 3 | GGACCACAGACAUAGUAGAAt | UCUACUAUGUCUGUGGUCCcg |
| NM_020967 | NCOAS | nuclear receptor coactivator 5 | s33689 | 4 | ccguvacagagauagcuuut | AAAGCUAUCUCUGUAACGGtc |
| NM_020967 | NCOAS | nuclear receptor coactivator 5 | s33690 | 3 | GGAUUUUCGAGAUCAGCGAtt | UCGCUGAUCUCGAAAAUCCCt |
| NM_014223 | NFYC | nuclear transcription factor $Y$, gamma | s9534 | Not Determined | GGAAUUUAACAGUGAAAGAtt | UCUUUCACUGUUAAAUUCCgg |
| NM_014223 | NFYC | nuclear transcription factor $Y$, gamma | s9535 | Not Determined | GGCUCGUAUUAAGAAGAUUUT | AAUCUUCUUAAUACGAGCCag |
| NM_014223 | NFYC | nuclear transcription factor $Y$, gamma | s9536 | Not Determined | GGCAGAUCAUCAUCGCACAAt | UGUGCGAUGAUGAUCUGCCca |
| NM_002592 | PCNA | proliferating cell nuclear antigen | s10133 | 5,4 | cGUAUAUGCCGAGAUCUCAAt | UGAGAUCUCGGCAUAUACGIg |
| NM_002592 | PCNA | proliferating cell nuclear antigen | s10134 | 5,4 | GGAGUGAAAUUUUCUGCAAtt | UUGCAGAAAAUUUCACUCCgt |
| NM_002592 | PCNA | proliferating cell nuclear antigen | s10135 | 3,2 | GAAGAUAUCAUUACACUAAIt | UUAGUGUAAUGAUAUCUUCat |
| NM_013374 | PDCD6IP | programmed cell death 6 interacting protein | s19465 | Not Determined | GAAGGAUGCUUUCGAUAAAAI | UUUAUCGAAAGCAUCCUUCca |
| NM_013374 | PDCDGIP | programmed cell death 6 interacting protein | s19466 | Not Determined | GCUAUAAUCCUUAUGCGUAAt | UACGCAUAAGGAUUAUAGCcc |


| NM_013374 | PDCD6IP | programmed cell death 6 interacting protein | s19467 | Not Determined | GAAUUACUGCAACGAAAUAAtt | UAUUUCGUUGCAGUAAUUCag |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| NM_001009552 | PPP2CB | protein phosphatase 2, catalytic subunit, beta isozyme | s10960 | 2 | GGAUAUUAUUCAGUGGAGAtt | UCUCCACUGAAUAAUAUCCIt |
| NM_001009552 | PPP2CB | protein phosphatase 2, catalytic subunit, beta isozyme | s10961 | 6 | CAAUUACUGUUAUCGUUGUUt | ACAACGAUAACAGUAAUUGgg |
| NM_001009552 | PPP2CB | protein phosphatase 2 , catalytic subunit, beta isozyme | s10962 | 3 | CAAUAUUGAGAGGAAAUCAIt | UGAUUUCCUCUCAAUAUUGta |
| NM_018312 | SAPS3 | SAPS domain family, member 3 | s30657 | Not Determined | GGUUACAUGGGACACCUAAtt | UUAGGUGUCCCAUGUAACCat |
| NM_018312 | SAPS3 | SAPS domain family, member 3 | s30658 | Not Determined | GAUGAAUCCUUGCUAAUGAtt | UCAUUAGCAAGGAUUCAUCtt |
| NM_018312 | SAPS3 | SAPS domain family, member 3 | s445949 | Not Determined | GGAAAACUGUUACCAGGAUIt | AUCCUGGUAACAGUUUUCCtc |
| NM_002734 | PRKAR1A | protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1) | s286 | 11,11,11 | GGACCGACCUAGAUUUGAAAtt | UUCAAAUCUAGGUCGGUCCag |
| NM_002734 | PRKAR1A | protein kinase, cAMP-dependent, regulatory, type I , alpha (tissue specific extinguisher 1 ) | s287 | 6,6,6 | CUAUGUGAUUGAUCAAGGAtt | UCCUUGAUCAAUCACAUAGaa |
| NM_002734 | PRKAR1A | protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1) | s288 | 3,3,3 | CGGCAUCCUAUGUUAGAAAtt | UUUCUAACAUAGGAUGCCGca |
| NM_001081640 | PRKDC | protein kinase, DNA-activated, catalytic polypeptide | s773 | 31,31 | GCGUUGGAGUGCUACAACAtt | UGUUGUAGCACUCCAACGCgg |
| NM_001081640 | PRKDC | protein kinase, DNA-activated, catalytic polypeptide | s774 | 6,6 | GCGCUUUUCUGGGUGAACUIt | AGUUCACCCAGAAAAGCGCgg |
| NM_001081640 | PRKDC | protein kinase, DNA-activated, catalytic polypeptide | s775 | 27,27 | CAAGCGACUUUAUAGCCUUIt | AAGGCUAUAAAGUCGCUUGaa |
| NM_002763 | PROX1 | prospero homeobox 1 | S11227 | 2 | CCUGAAUCCUUAGACUUAAtt | UUAAGUCUAAGGAUUCAGGag |
| NM_002763 | PROX1 | prospero homeobox 1 | s11228 | 2 | GUUUGAUAUGGAUCGCUUAtt | UAAGCGAUCCAUAUCAAACtg |
| NM_002763 | PROX1 | prospero homeobox 1 | S11229 | 3 | CGACGUAAAGUUCAACAGAtt | UCUGUUGAACUUUACGUCGga |
| NM_005610 | RBBP4 | retinoblastoma binding protein 4 | S11837 | Not Determined | GGAUACUCGUUCAAACAAUtt | AUUGUUUGAACGAGUAUCCca |
| NM_005610 | RBBP4 | retinoblastoma binding protein 4 | s11838 | Not Determined | CUUGUAUCAUCGCAACAAAAt | UUUGUUGCGAUGAUACAAGgg |
| NM_005610 | RBBP4 | retinoblastoma binding protein 4 | s11839 | Not Determined | CAGUGGUACUGAUCGCAGAtt | UCUGCGAUCAGUACCACUGga |
| NM_002893 | RBBP7 | retinoblastoma binding protein 7 | s11846 | Not Determined | GCUUUAUGGGAUCUGCGUAtt | UACGCAGAUCCCAUAAAGCta |
| NM_002893 | RBBP7 | retinoblastoma binding protein 7 | S11847 | Not Determined | GGAAGAAGAAUACACCGUUtt | AACGGUGUAUUCUUCUUCCag |
| NM_002893 | RBBP7 | retinoblastoma binding protein 7 | s11848 | Not Determined | CUCACAUCAUUGCUACAAAIt | UUUGUAGCAAUGAUGUGAGga |
| NM_015156 | RCOR1 | REST corepressor 1 | s23229 | 5 | GAGUGGACUGUGGAAGAUAtt | UAUCUUCCACAGUCCACUCat |
| NM_015156 | RCOR1 | REST corepressor 1 | s23230 | 8 | GGAAUUGGUUUCAGUCAAAAt | UUUGACUGAAACCAAUUCCat |
| NM_015156 | RCOR1 | REST corepressor 1 | s23231 | 6 | CCAGAUAAAUCUAUAGCAAtt | UUGCUAUAGAUUUAUCUGGaa |
| NM_007212 | RNF2 | ring finger protein 2 | s12067 | 5 | GGCUAGAGCUUGAUAAUAAIt | UUAUUAUCAAGCUCUAGCCca |
| NM_007212 | RNF2 | ring finger protein 2 | s12068 | 5 | CAAACGGACCAAAACAUCUIt | AGAUGUUUUGGUCCGUUUGtt |
| NM_007212 | RNF2 | ring finger protein 2 | s12069 | 3 | GGAGUGUUUACAUCGUUUUIt | AAAACGAUGUAAACACUCCIt |
| NM_004348 | RUNX2 | runt-related transcription factor 2 | s2455 | 4 | CUUGAUGACUCUAAACCUAtt | UAGGUUUAGAGUCAUCAAGct |
| NM_004348 | RUNX2 | runt-related transcription factor 2 | s2456 | 7 | CCAAAUUUGCCUAACCAGAtt | UCUGGUUAGGCAAAUUUGGat |
| NM_004348 | RUNX2 | runt-related transcription factor 2 | s2457 | 4 | CAAGUCCUUUUAAUCCACAtt | UGUGGAUUAAAAGGACUUGgt |
| NM_001001890 | RUNX1 | runt-related transcription factor 1 | s2458 | 5,8 | CCAAUACCUGGGAUCCAUUIt | AAUGGAUCCCAGGUAUUGGta |
| NM_001001890 | RUNX1 | runt-related transcription factor 1 | s2459 | 2,5 | GAACCAGGUUGCAAGAUUUIt | AAAUCUUGCAACCUGGUUCtt |
| NM_001001890 | RUNX1 | runt-related transcription factor 1 | s229351 | 4,4,7 | GGCAGAAACUAGAUGAUCAtt | UGAUCAUCUAGUUUCUGCCga |
| NM_002971 | SATB1 | SATB homeobox 1 | s12479 | Not Determined | GGCUCGUAUCAACACCUAUtt | AUAGGUGUUGAUACGAGCCca |
| NM_002971 | SATB1 | SATB homeobox 1 | s12480 | Not Determined | CGAAUAUACCAGGACGAAAtt | UUUCGUCCUGGUAUAUUCGgt |
| NM_002971 | SATB1 | SATB homeobox 1 | s12481 | Not Determined | GCAUUGCUGUCUCUAGGUUIt | AACCUAGAGACAGCAAUGCca |
| NM_015265 | SATB2 | SATB homeobox 2 | s23539 | Not Determined | CCACAGUACUCCAAUCCGAtt | UCGGAUUGGAGUACUGUGGtg |
| NM_015265 | SATB2 | SATB homeobox 2 | s23540 | Not Determined | GUCCACAACUUGUAAGGCAtt | UGCCUUACAAGUUGUGGACta |
| NM_015265 | SATB2 | SATB homeobox 2 | s223583 | Not Determined | GCAUUACAGCCCAUCAUGAtt | UCAUGAUGGGCUGUAAUGCgg |
| NM_012238 | SIRT1 | sirtuin (silent mating type information regulation 2 homolog) 1 (S. cerevisiae) | s23771 | Not Determined | GGGUCUUCCCUCAAAGUAAAt | UUACUUUGAGGGAAGACCCaa |
| NM_012238 | SIRT1 | sirtuin (silent mating type information regulation 2 homolog) 1 (S. cerevisiae) | s223591 | Not Determined | CAACUAUACCCAGAACAUAIt | UAUGUUCUGGGUAUAGUUGcg |
| NM_012238 | SIRT1 | sirtuin (silent mating type information regulation 2 homolog) 1 (S. cerevisiae) | s223592 | Not Determined | CCCUCAAAGUAAGACCAGUtt | ACUGGUCUUACUUUGAGGGaa |
| NM_003072 | SMARCA4 |  | s13139 | Not Determined | GGAAUACCUCAAUAGCAUUtt | AAUGCUAUUGAGGUAUUCCtg |
| NM_003072 | SMARCA4 |  | s13140 | Not Determined | GGCUUGAUGGAACCACGAAtt | UUCGUGGUUCCAUCAAGCCtg |
| NM_003072 | SMARCA4 |  | s13141 | Not Determined | GUAGCUCCGAGGUCUGAUAtt | UAUCAGACCUCGGAGCUACtt |
| NM_003601 | SMARCA5 |  | s16081 | 7 | GGAGAUACUUAGUAAUAGAtt | UCUAUUACUAAGUAUCUCCaa |
| NM_003601 | SMARCA5 |  | s16082 | 3 | GGGCAAAUAGAUUCGAGUAAtt | UACUCGAAUCUAUUUGCCCgg |
| NM_003601 | SMARCA5 |  | s16083 | 16 | GGGCGAAAGUUCACUUAGAtt | UCUAAGUGAACUUUCGCCCat |
| NM_003074 | SMARCC1 |  | s13145 | Not Determined | CCAACACCUGUACCCAAUAAt | UAUUGGGUACAGGUGUUGGgt |
| NM_003074 | SMARCC1 |  | s13146 | Not Determined | CAAGAGUAUUUAACUAGCAtt | UGCUAGUUAAAUACUCUUGgg |
| NM_003074 | SMARCC1 | 3 ? | s13147 | Not Determined | CCAUCUCGAAUGGAUCGUAAt | UACGAUCCAUUCGAGAUGGgt |
| NM_003079 | SMARCE1 |  | s13160 | 6 | GCAGAAAAGAUAGAGUACAtt | UGUACUCUAUCUUUUCUGCEt |
| NM_003079 | SMARCE1 |  | s13161 | 7 | GUACCUUGCUUACAUAAAUIt | AUUUAUGUAAGCAAGGUACgc |
| NM_003079 | SMARCE1 |  | s13162 | 6 | GACCUAAAGUUGUGGGAGAtt | UCUCCCACAACUUUAGGUCag |
| NM_001039590 | USP9X | ubiquitin specific peptidase 9, X -linked | s15742 | 19,19 | GAUGUAUUCUCAAUCGUAUtt | AUACGAUUGAGAAUACAUCgt |
| NM_001039590 | USP9X | ubiquitin specific peptidase 9, X -linked | s15743 | 18,18 | CAGUGUUAAUUGUGCAAGAtt | UCUUGCACAAUUAACACUGtc |
| NM_001039590 | USP9X | ubiquitin specific peptidase $9, \mathrm{X}$-linked | s15744 | 33,33 | GCCUGUUAAUCUGCGUGAAtt | UUCACGCAGAUUAACAGGCtc |
| NM_017588 | WDR5 | WD repeat domain 5 | s225470 | 5,4 | GCCUGGUCGUCAGAUUCUAtt | UAGAAUCUGACGACCAGGCta |
| NM_017588 | WDR5 | WD repeat domain 5 | s21863 | 13,12 | CGAAAGAGAUUGUACAGAAtt | UUCUGUACAAUCUCUUUCGtc |
| NM_017588 | WDR5 | WD repeat domain 5 | s21864 | 4,3 | GAUGGGAAAUUUGAGAAAAtt | UUUUCUCAAAUUUCCCAUCat |
| NM_001128128 | ZEB1 | zinc finger E-box binding homeobox 1 | s229971 | 7,7 | GGUAGAUGGUAAUGUAAUAIt | UAUUACAUUACCAUCUACCgc |
| NM_001128128 | ZEB1 | zinc finger E-box binding homeobox 1 | s229972 | 7,7 | GGACAGCACAGUAAAUCUAtt | UAGAUUUACUGUGCUGUCCtg |
| NM_030751 | ZEB1 | zinc finger E-box binding homeobox 1 | s13883 | 6 | CAGUCUGGGUGUAAUCGUAtt | UACGAUUACACCCAGACUGcg |
| NM_014795 | ZEB2 | zinc finger E-box binding homeobox 2 | s19032 | Not Determined | CCGGAGUUUUUGUUGAUAAtt | UUAUCAACAAAAACUCCGGct |
| NM_014795 | ZEB2 | zinc finger E-box binding homeobox 2 | s19033 | Not Determined | GGAAUGGUUUGAACAACGAtt | UCGUUGUUCAAACCAUUCCtt |
| NM_014795 | ZEB2 | zinc finger E-box binding homeobox 2 | s19034 | Not Determined | CCACAACAGUGUUACGAAUtt | AUUCGUAACACUGUUGUGGag |
| NM_021964 | ZNF148 | zinc finger protein 148 | s15207 | 9 | GCAUAGUAGUACUAAUUAUtt | AUAAUUAGUACUACUAUGCac |
| NM_021964 | ZNF148 | zinc finger protein 148 | s15208 | 9 | GUAUUGAAACAUAAACGUAAtt | UACGUUUAUGUUUCAAUACac |
| NM_021964 | ZNF148 | zinc finger protein 148 | s15209 | 6 | GAACUAUCACUUACAGAGAtt | UCUCUGUAAGUGAUAGUUCgt |
| NM_001039916 | ZNF384 | zinc finger protein 384 | s46887 | 7,8,7,7,7,8 | CCACACUGGUGAUAGACCAtt | UGGUCUAUCACCAGUGUGGat |
| NM_001039916 | ZNF384 | zinc finger protein 384 | s46888 | 9,10,9,9,9,10 | CAGUGUUCCUUUGACCUGAtt | UCAGGUCAAAGGAACACUGgg |
| NM_001039916 | ZNF384 | zinc finger protein 384 | s46889 | 9,10,9,9,9,10 | CAUACCUUAUGAAACAUAUIt | AUAUGUUUCAUAAGGUAUGtt |
| NM_181781 | ZNF326 | zinc finger protein 326 | s195971 | Not Determined | GGAUCGUGAUUAUGGCCCUIt | AGGGCCAUAAUCACGAUCCat |
| NM_181781 | ZNF326 | zinc finger protein 326 | s195972 | Not Determined | UAUCAGGGCUUUAAUGGAAAt | UUCCAUUAAAGCCCUGAUAag |
| NM_181781 | ZNF326 | zinc finger protein 326 | s195973 | Not Determined | AUACUUAUCAGGGCUUUAAtt | UUAAAGCCCUGAUAAGUAUTC |
| NM_006510 | TRIM27 | tripartite motif containing 27 | s11959 | 2 | GCUGAACUCUUGAGCCUAAtt | UUAGGCUCAAGAGUUCAGCtc |
| NM_006510 | TRIM27 | tripartite motif containing 27 | s11960 | 5 | CAAAAAUGUCUAUUCUUGAtt | UCAAGAAUAGACAUUUUUGgg |
| NM_006510 | TRIM27 | tripartite motif containing 27 | s11961 | 3 | GCAGCUGUAUCACUCCUUAtt | UAAGGAGUGAUACAGCUGCtc |

Supplementary Table S3: Leading edge subset

|  | Protein name | Gen name | RANK IN GENE LIST | RANK METRIC SCORE | RUNNING ES | CORE ENRICHMENT |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | Isochorismatase domain-containing protein 1 | ISOC1 | 0 | 3.698696613 | 0.025464967 | Yes |
| 2 | Sodium bicarbonate transporter 4 | NBC4 | 35 | 2.496522188 | 0.041109372 | Yes |
| 3 | Manosidase, enod-alpha | MANEA | 66 | 2.140193939 | 0.054482136 | Yes |
| 4 | Heart development protein with EGF-like domains 1 | HEG1 | 93 | 1.947881818 | 0.06671248 | Yes |
| 5 | Tripartit motiv containing | TRIM58 | 95 | 1.92384994 | 0.07991248 | Yes |
| 6 | DTW domain-containing protein 1 | DTWD1/MDS009 | 101 | 1.893535733 | 0.09272217 | Yes |
| 7 | Interphotoreceptor mmatrix proteoglycan 1 | IMPG1 | 117 | 1.822807193 | 0.10459085 | Yes |
| 8 | Transmembrane protein 202 | TMEM202 | 124 | 1.790550351 | 0.11664608 | Yes |
| 9 | Analplastic lymphoma receptor tyrosine kinase | ALK | 132 | 1.776676178 | 0.1285604 | Yes |
| 10 | P -cadherin | CDH3 | 409 | 1.318120718 | 0.13671853 | Yes |
| 11 | Tissue inhibitor of metalloproteinase 3 | TIMP3 | 417 | 1.312698364 | 0.14543843 | Yes |
| 12 | Pleiomorphic adenoma gene-like 1 | PLAGL1 | 474 | 1.258885026 | 0.15156297 | Yes |
| 13 | Fas apoptotic inhibitory molecule | FAIM | 497 | 1.244239688 | 0.15913047 | Yes |
| 14 | Tuftelin interacting protein 11 | TFIP11 | 518 | 1.232141018 | 0.16670547 | Yes |
| 15 | Leucine zipper putative tumor suppressor 3 | LZTS3 | 522 | 1.229026198 | 0.17503092 | Yes |
| 16 | Transricption factor E4TF1-60 | E4TF1-60 | 530 | 1.224172235 | 0.18314132 | Yes |
| 17 | Teneurin 3 | TENM3 | 571 | 1.20076251 | 0.1895922 | Yes |
| 18 | Hypoxia-inducible factor-2alpha | EPAS1 | 588 | 1.187447548 | 0.19704111 | Yes |
| 19 | RNA-binding Protein 35B | RBM35B | 607 | 1.179178596 | 0.21254866 | Yes |
| 20 | Calcium channel, voltage-dependent, beta 2 subunit | CACNB2 | 690 | 1.123668432 | 0.22459577 | Yes |
| 21 | Bone morphogenetic protein 5 | BMP5 | 710 | 1.112659931 | 0.23139356 | Yes |
| 22 | Plakophilin 1 | PKP1 | 766 | 1.08441925 | 0.23636235 | Yes |
| 23 | Spermidinespermine N1-acetyltransferase | SAT1 | 794 | 1.069862843 | 0.24250226 | Yes |
| 24 | Tousled-like kinase 1 | TLK1 | 1024 | 0.976659536 | 0.23882866 | Yes |
| 25 | Coiled-coil domain containing 121 | CCDC121 | 1113 | 0.947796762 | 0.24135846 | Yes |
| 26 | Microtubule plus-end tracking protein TIP150 | TIP150/MTUS2 | 1119 | 0.945643008 | 0.24764204 | Yes |
| 27 | Synaptic Vesicle Glycoprotein 2a | SV2A | 1121 | 0.945068359 | 0.2541033 | Yes |
| 28 | Transcription factor AP2beta | TFAP2beta | 1129 | 0.942483664 | 0.26027432 | Yes |
| 29 | 2-5oligoadenylate synthetase 2 | OAS2 | 1232 | 0.907269478 | 0.26188943 | Yes |
| 30 | F-box only protein 17 | FBXO17 | 1353 | 0.873526156 | 0.2624549 | Yes |
| 31 | Calcium-activated potassium channel SK3 | KCNN3 | 1439 | 0.852016211 | 0.2644615 | Yes |
| 32 | Glycine amidinotransferase | GATM | 1470 | 0.844306111 | 0.26891226 | Yes |
| 33 | Cytochrome P450 polypeptide 43 | CYP3A43 | 1491 | 0.840080678 | 0.27378798 | Yes |
| 34 | Centrosomal protein of 104 kDa | CEP104 | 1537 | 0.825581908 | 0.27742878 | Yes |
| 35 | Disrupted in schizophrenia 1 | DISC1 | 1785 | 0.776802301 | 0.2715619 | Yes |
| 36 | Complement decay-accelerating factor for complement | CD55 | 1829 | 0.769265771 | 0.27490577 | Yes |
| 37 | Serinethreonine kinase RICK | RICK | 1885 | 0.758343697 | 0.27762955 | Yes |
| 38 | Rho guanine nucleotide exchange factor 3 | ARHGEF3 | 1949 | 0.745236158 | 0.2798999 | Yes |
| 39 | Meiotic recombination protein DMC1/LIM15 homolog | HsLim15/DCM1 | 1968 | 0.741775393 | 0.2841896 | Yes |
| 40 | Metallophosphoesterase 1 | MPPE1 | 2040 | 0.725010157 | 0.28595743 | Yes |
| 41 | Mitochondrial NAD(P)+ dependent malic enzyme | ME2 | 2158 | 0.70450604 | 0.28549546 | Yes |
| 42 | Cyclin-dependent kinase 3 | CDK3 | 2217 | 0.694423258 | 0.287643 | Yes |
| 43 | Membrane metallo-endopeptidase | MME | 2223 | 0.693363011 | 0.29218966 | Yes |
| 44 | Ankyrin 2, neuronal | ANK2 | 2297 | 0.681526303 | 0.2935673 | Yes |
| 45 | Adrenergic, beta-1-, receptor | ADRB1 | 2318 | 0.67876333 | 0.29733238 | Yes |
| 46 | Ras supressor 1 | RSU1 | 2345 | 0.673559248 | 0.3007892 | Yes |
| 47 | Na+/K+ Transporting ATPase Interacting 1 | NKAIN1 | 2379 | 0.668322086 | 0.30389214 | Yes |

## Supplementary Methods

Plasmids, transfection methods and lentiviral transduction. FLAG-tagged PAX3-FOXO1 was generated by inserting the cDNA into pCMV-SC-NF or pCMV-SC-CF (N/C-terminal 3xFLAG, Stratagene, Agilent Technologies). FLAG-PAX3-FOXO1 was subcloned into pBABE puro (Addgene, no. 1764) using In-Fusion® HD Cloning Kit (Takara Bio Europe/Clontech) according to the manufacturer’s instructions. The vector pCMV-SC-CFFLAG only was used as negative control for immunoprecipitation and was generated by introducing a start codon into the parental pCMV-SC-CF vector. RH4 and RMS13 cells were transfected using JetPrimeTM (Polyplus-Transfections) and 293T cells grown in 6 cm dishes were transfected with plasmid DNA by the $\mathrm{CaPO}_{4}$ co-precipitation method. For transduction we used tet-inducible lentiviral shRNA expression vectors, containing indicated shRNAs (Cellecta, BioCat GmbH, Supplementary Table S4). Lentiviral packaging and envelope plasmids (pMDL, pREV and pVSV-G kindly provided by Oliver Pertz, Department of Biomedicine, University of Basel, Switzerland) were co-transfected into HEK293T cells using $\mathrm{CaPO}_{4}$. After 48 hrs, we collected virions from supernatant cultures and concentrated these using Amicon Ultra tubes, (Ultracel 100k, Millipore). RH4, RMS, RD, MRC5 and myoblast cells were transduced for 24 hrs in the presence of $8 \mathrm{ug} / \mathrm{ml}$ polybrene (Sigma-Aldrich). 72 hrs after transduction we started selection with puromycin with the exception of transduced myoblast cells, which were subjected to fluorescence activated cell sorting. For experiments shRNA expression was induced using $100 \mathrm{ng} / \mathrm{ml}$ doxycycline (Sigma-Aldrich). Data were normalized to uninduced and related to scrambled shRNA expressing cells.

## Supplementary Table S4: shRNA hairpin sequences

| Name | shRNA sequence $\mathbf{5}$ to $\mathbf{3}$ ` |
| :--- | :--- |
| shscr | ACCGGCAACAAGATGGAGAGCACTAAGTTAATATTCATAGCTTGGTGCTCTTCATCTTGTTGTTTT |
| shLSD1\#1 | ACCGGGCTACATCTTACCTTAGTTATGTTAATATTCATAGCATGACTAAGGTAAGATGTAGCTTTT |
| shLSD1\#2 | ACCGGGGAAGTTGTCATTCAGTTATAGTTAATATTCATAGCTGTAACTGAATGACAACTTCCTTTT |
| shCHD4\#1 | ACCGGGCGGGAGTTTAGTACTAATAAGTTAATATTCATAGCTTATTGGTACTGAACTCCCGCTTTT |
| shCHD4\#2 | ACCGGCCTCGAGTGAGGGTGATGATTGTTAATATTCATAGCAGTCATCATCCTCACTCGAGGTTTT |
| shPAX3-FOXO1 | ACCGGGGCCTCTCACCTCAGAATTCAGTTAATATTCATAGCTGAATTCTGAGGTGAGAGGCCTTTT |

Mass spectrometry. Samples were analyzed on a LTQ-Orbitrap Classic mass spectrometer (Thermo Fischer Scientific) coupled to an Eksigent-Nano-HPLC system (Eksigent Technologies). Solvent composition at the two channels was $0.2 \%$ formic acid, $1 \%$ acetonitrile for channel A and $0.2 \%$ formic acid, $80 \%$ acetonitrile for channel B. Peptides were resuspended in $3 \%$ ACN and $0.2 \%$ formic acid and loaded on a self-made tip column $(75 \mu \mathrm{~m} \times 70 \mathrm{~mm})$ packed with reverse phase C18 material (AQ, $3 \mu \mathrm{~m} 200 \AA$, Bischoff GmbH ) and eluted with a flow rate of 200 nl per min by a gradient from 3 to $35 \%$ of B in $55 \mathrm{~min}, 48 \%$ B in 60min, $97 \%$ B in 68min. Full-scan MS spectra (300-2000 m/z) were acquired with a resolution of 60000 at $400 \mathrm{~m} / \mathrm{z}$ after accumulation to a target value of 500000 .

Collision induced dissociation (CID) MS/MS spectra were recorded in data dependent manner in the ion trap from the five most intense signals above a threshold of 500 , using a normalized collision energy of $28 \%$ and an activation time of 30 ms . Charge state screening was enabled and singly charge states were rejected. Precursor masses selected twice for MS/MS were excluded for further selection for 120s. The exclusion window was set to 20 ppm , while the size of the exclusion list was set to a maximum of 500 entries. Samples were acquired using internal lock mass calibration set on $\mathrm{m} / \mathrm{z} 429.088735$ and 445.120025.

Database search and protein identification. The raw-files from the mass spectrometer were converted into Mascot generic files (mgf) with Mascot Distiller software 2.4.2.0 (Matrix Science Ltd.,London, UK). The peak lists were searched using Mascot Server 2.3 against the forward UniProtKB/Swiss-Prot database for human, concatenated to a reversed decoyed FASTA database consisting of a total of 135,183 proteins with accessions in Gene Ontology compatible format and 260 common protein contaminants (NCBI taxonomy ID 9606, release date 2012-04-12). The protein sequence of PAX3-FOXO1 (gi|431254|gb|AAC50053.1|) was included in the database as in reference (1). The parameters for precursor tolerance and fragment ion tolerance were set to $\pm 5 \mathrm{ppm}$ and $\pm 0.8 \mathrm{Da}$, respectively. Carbamidomethylation of cysteine was set as fixed modification, while phosphorylation (S, T, Y ) and oxidation (M) were set as variable. The results were loaded into Scaffold 4.0
(Proteome Software, Portland, US) and filtered for peptides with a minimum mascot score of 20 and peptide probability higher than $95 \%$, protein probability greater than $99 \%$ and minimum of 2 peptides per protein.

Quantitative Real Time PCR. Total RNA was extracted using the Qiagen RNeasy Kit and reverse transcription was carried out using high-capacity cDNA reverse transcription kit (Life Technologies) according to the manufacturer's instructions. Quantitative Real Time PCR was performed using commercially available TaqMan gene expression master mix and assays (all Life Technologies, Supplementary Table S5). Reactions were run using standard conditions on an ABI 7900 HT Real Time PCR machine and the data were analyzed with SDS 2.3 software. $\mathrm{C}_{\mathrm{T}}$ values were normalized to GAPDH and relative expression levels were calculated using the $\Delta \Delta C_{T}$ method based on experiments performed in triplicates. Data analysis was done with the GraphPad prism software, version 6.

## Supplementary Table S5: TaqMan Gene Expression Assays

| Name | Assay |
| :--- | :--- |
| CHD4 | Hs00172349_m1 |
| LSD1 | Hs01002741_m1 |
| PAX3-FOXO1 | Hs03024825_ft |
| TFAP2B | Hs00231468_m1 |
| CDH3 | Hs00999918_m1 |
| NMYC | Hs00232074_m1 |
| PIPOX | Hs04188864_m1 |
| MYL1 | Hs00984899_m1 |
| GAPDH | Hs02758991_g1 |
| CB1 | Hs01038522_s1 |
| ALK | Hs00608284_m1 |

For ChIP-qPCR Taqman assays spanning recently identified PAX3-FOXO1 binding sites at regulatory regions of various direct target genes, or the GAPDH promoter region as negative control were designed (all Microsynth AG, Supplementary Table S6) (2). Quantity of purified ChIP-DNA was determined by absolute quantification using standard curves and normalized to the amount of input material. Fold enrichment was calculated relative to the shscr noninduced control.

| Name | Sequence $\mathbf{5}^{\text {to }} \mathbf{3}$ ' |
| :--- | :--- |
| CDH3 fwd | ATGCTCCCGAGATACCAGAT |
| CDH3 rev | AGAAGCGTTGTAATCCTCCAA |
| CDH3 probe | TGCTCGTTGTACCCTCAGCCATG |
| GAPDH fwd | CCAATCTCAGTCCCTTCCC |
| GAPDH rev | GGTCTTGAGGCCTGAGCTAC |
| GAPDH probe | CCCAGTTGAACCAGGCGGCT |
| PIPOX fwd | GGGATTTCCACTGCATCTTT |
| PIPOX rev | CAGCGAGATAGCAACGAGAG |
| PIPOX probe | TGCCTCTTCGAAGCTCAACAGAGG |
| FGFR4 fwd | CCCTGAGAAGTGGTTGAGG |
| FGFR4 rev | GGAAAGCTGGGTGAGTTCAG |
| FGFR4 probe | CTGTTGGCGATTTCACGCCC |
| NMYC fwd | CAGGGTGGGTTACACCGT |
| NMYC rev | CTCATTACACCAATTCCTGGAG |
| NMYC probe | AACAGCTGCCACCGGCAAGA |

FOXO1 silencing. Knockdown of FOXO1 prior immunoprecipitation was achieved by reverse transfection of $4 \times 10^{6}$ cells in 15 cm plates using 8.6 nM scrambled (4390846) or FOXO1 directed siRNAs (siscr: 4390846, siFOXO1\#1: s456610, siFOXO1\#2: s456611 all Ambion, Life Technologies) with INTERFERin ${ }^{\top \mathrm{M}}$ according to the manufacturer's protocol (Polyplus-Transfections). Cells were lysed 72 hours post transfection.

Antibodies. Western blot membranes were incubated with anti-FOXO1 (H-128) (sc-11350; 1:1000; Santa Cruz Biotechnology), anti-LSD1 (C69G12) (2184; 1:1000; Cell Signaling), antiCHD4 (A301-082A, 1:1000; Bethyl Laboratories), anti-HDAC1 (10E2) (5356; 1:1000; Cell Signaling) anti-HDAC2 (3F3) (5113; 1:1000; Cell Signaling) anti-Cleaved Caspase-7 (Asp198) (9491; 1:1000; Cell Signaling) anti-PARP (9542; 1:1000; Cell Signaling) antibodies. Anti- $\beta$-Tubulin mouse mAb (1:40,000; Sigma-Aldrich), anti- $\beta$-Actin (13E5) rabbit mAb (4970; 1:1000; Cell Signaling) and anti-GAPDH (D16H11) XP ${ }^{\text {TM }}$ rabbit mAb (5174; 1:1000; Cell Signaling) were used as loading controls. Membranes were incubated with the secondary antibodies anti-mouse IgG HRP-linked antibody (7076; 1:2000; Cell Signaling), anti-rabbit IgG HRP-linked antibody (7074; 1:2000; Cell Signaling), EasyBlot anti-mouse IgG HRP-
linked antibody (GTX221667-01; 1:1000; Genetex) or EasyBlot anti-rabbit IgG HRP-linked antibody (GTX221666-01; 1:1000; Genetex) for one hour at room temperature. IP experiments were performed using anti-FOXO1 (C-20) (sc-9808; Santa Cruz Biotechnology) and monoclonal ANTI-FLAG® M2 antibody (F1804, Sigma-Aldrich). Reverse IP was performed with anti-CHD4 (A301-082A, polyclonal, rabbit, Bethyl Laboratories) and chromatin immunoprecipitations were performed using anti-CHD4 antibody (ab70469, [3F2/4] ChIP Grade, Abcam) and anti-Pax3/7 (N-19) (sc-7749X; goat, polyclonal, Santa Cruz Biotechnology).

Tissue arrays. Tissue arrays have been previously described (3). Briefly, three-micron thick sections of a tissue microarray representing formalin-fixed, paraffin-embedded tissues from 58 FP-RMS and 203 FN-RMS tumors were mounted on glass slides (SuperFrost Plus; Menzel, Braunschweig, Germany), deparaffinized, rehydrated and stained with hematoxylin and eosin (H\&E) using standard histological techniques. Immunohistochemistry was performed with anti-CHD4 ChIP Grade (Abcam Limited, ab70469, dilution 1:500) as described in the immunohistochemistry section. For evaluation of stainability of individual tissue cores, a separate section of the tissue array was stained with the general RMS marker Desmin and only Desmin-positive tumors were selected for further analysis. Furthermore, only FP-RMS tumors for which PAX3-FOXO1 fusion status has been verified or which express TFAP2 $\beta$, a marker of FP-RMS, have been included in the analyses (3).

1 Shapiro DN, Sublett JE, Li B, Downing JR, Naeve CW. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer research. 1993 Nov 1;53(21):5108-12.
2 Cao L, Yu Y, Bilke S, et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer research. 2010 Aug 15;70(16):6497-508.
3 Wachtel M, Runge T, Leuschner I, et al. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Feb 10;24(5):816-22.

1 MTTLAGAVPR MMRPGPGQNY PRSGFPLEVS TPLGQGRVNQ LGGVFINGRP 51 LPNHIRHKIV EMAHHGIRPC VISRQLRVSH GCVSKILCRY QETGSIRPGA 101 IGGSKPKQVT TPDVEKKIEE YKRENPGMFS WEIRDKLLKD AVCDRNTVPS 151 vSSISRILRS KFGKGEEEEA DLERKEAEES EKKAKHSIDG ILSERASAPQ 201 SDEGSDIDSE PDLPLKRKQR RSRTTFTAEQ LEELERAFER THYPDIYTRE 251 ELAQRRAKLTE ARVQVWFSNR RARWRKQAGA NQLMAFNHLI PGGFPPTAMP 301 TLPTYQLSET SYQPTSIPQA VSDPSSTVHR PQPLPPSTVH QSTIPSNPDS 351 SSAYCLPSTR HGFSSYTDSF VPPSGPSNPM NPTIGNGLSP QNS 1 RHNLSL 401 HSKFIRVQNE GTGKSSWWML NPEGGKSGKS PRRRAASMDN NSKFAKSRSR 451 AAKKKASLQS GQEGAGDSPG SQFSKWPASP GSHSNDDFDN WSTFRPRTSS 501 NASTISGRLS PIMTEQDDLG EGDVHSMVYP PSAAKMASTL PSLSEISNPE 551 NMENLLDNLN LLSSPTSLTV STQSSPGTMM QQTPCYSFAP PNTSLNSPSP 601 NYQKYTYGQS SMSPLPQMPI QTLQDNKSSY GGMSQYNCAP GLLKELLTSD 651 SPPHNDIMTP VDPGVAQPNS RVLGQNVMMG PNSVMSTYGS QASHNKMMNP 701 SSHTHPGHAQ QTSAVNGRPL PHTVSTMPHT SGMNRLTQVK TPVQVPLPHP 51 MQMSALGGYS SVSSCNGYGR MGLLHQEKLP SDLDGMFIER LDCDMESIIR 301 NDLMDGDTLD FNFDNVLPNQ SFPHSVKTTT HSWVSG

Supplementary Figure 1. Immunoprecipitation of FLAG-PAX3-FOXO1. (A) Qualitative comparison of different FLAG-PAX3-FOXO1 expression systems in RH4 and RMS13 cells. pCMV expression system for high over expression and pBABE for expression levels comparable to endogenous PAX3-FOXO1 expression level (wt). (B) Peptide sequence of the PAX3-FOXO1 fusion protein. Peptide sequences identified by mass spectrometry in RMS13 cells are marked in red and the break point of PAX3 and FOXO1 is indicated with a black vertical hatch mark.

| Protein | Biological Role |
| :---: | :---: |
| RBBP4 | Histone-binding, Scaffold protein in chromatin repressive complexes |
| CHD4 | ATP-dependent chromatin remodeler, (CHD family) |
| LSD1 | Histonedemethylase; Lysine-specific demethylation of H3 and proteins (e.g. p53) |
| BAZ1B/WSTF | Tyrosine kinase; phosphorylates H2AX during DNA damage response |
| Essential component of WSTF-ISWI (WICH) chromatin remodeling complex |  |
| RCOR1 | ATP-dependent chromatin remodeler, (CHD family) |
| MYOG/MYF4 | Component of the chromatin repressor complex CoREST |
| ZNF148 | Muscle determination factor, bHLH transcription factor |
| CCAR2 | Transcriptional repressor |



Supplementary Figure 3. Validation of LSD1, CHD4 and PAX3-FOXO1 silencing and effect on expansion of FP-RMS cell line RMS. (A) Knockdown of CHD4, LSD1 or PAX3-FOXO1 mRNA in indicated cell lines 72 hrs after induction with doxycycline as measured by qRTPCR. Bar charts are geometric means from three independent experiments with $95 \% \mathrm{Cl}(\star \star \star \star \mathrm{p}<0.0001$ Dunnett’s multiple comparison test). Fold changes of mRNA expression are normalized to uninduced controls.. (B) Western blots after knockdown of PAX3-FOXO1 or CHD4 in indicated aRMS cell extracts 72 hrs after induction with doxycycline (Dox.). Uninduced cells served as negative control and GAPDH was used as loading control. (C) Effect of CHD4 and PAX3-FOXO1 knockdown on expansion of the FP-RMS cell line RMS relative to uninduced control cells at indicated timepoints as measured by WST-assay.


Supplementary Figure 4. CHD4 knockdown induces cell death of FP-RMS cell line RMS in vitro. (A) Caspase 3/7 activity in RMS cells 72 hrs after induction of CHD4 silencing. Fold change of Caspase $3 / 7$ activity was normalized to the uninduced control cells (ctrl). Shscr treated cells served as negative and PAX3-FOXO1 knockdown cells as positive control. Values are means $\pm$ SD of three independent experiments. (B) Percentage of dead cells 96 hrs after treatment as in (A). Cells were stained with NucView caspase-3 substrate and 7-AAD and quantified by flow cytometry. Values are means $\pm$ SD of four independent experiments ( $\star \star \star \mathrm{p}<0.001 ; \star \mathrm{p}<0.05$; Uncorrected Fisher`s LSD). (C) Western blot of PARP and cleaved Caspase 7 using extracts from the FP-RMS cell line RMS 72 hrs after induction of CHD4 or PAX3-FOXO1 silencing and uninduced or shscr treated control cells. (D) Representative phase-contrast images of RMS cells 72 h after induction of silencing with doxycycline (Dox.) in indicated cell lines and uninduced control cells, magnification 100x. (E) Clonogenic assays on RMS cells at 12 days after induction of CHD4 silencing. Representative images for crystal violet stains and quantitation of number of colonies. The black bars represent the means.


Nucview 405 Caspase 3

Supplementary Figure 5. Detection of Caspase $3 / 7$ cleavage in individual cells by flow cytometry. (A) Percentage of Caspase $3 / 7$ positive cells 72 hrs after CHD4 knockdown in indicated FP-RMS cell lines and uninduced controls. Cells were stained with NucView 405 Caspase 3 substrate and quantified by flow cytometer. Values are means $\pm$ SD of four independent experiments ( $\star \star \star \star p<0.0001$; $\star \star$ p $<$ $0.01, \star p<0.05$; Uncorrected Fisher`s LSD). (B) FACS histograms of cells from (A). Histograms show number of cells after exclusion of cell doublets gated on forward and side scatter characteristics and percentage of $3 / 7$ positive and negative cells.


RH4

RMS

Nucview 405 Caspase 3

Supplementary Figure 6. Percentage of Caspase 3/7 and/or 7AAD positive FP-RMS cells. FACS histogram analysis of indicated cells 96 hrs after induction of CHD4 silencing with doxycycline and uninduced controls stained with Nucview 405 Caspase 3 substrate and 7AAD Plots show live and dead cells after exclusion of cell doublets gated on forward- and side scatter characteristics, and the percentage of DAPI and 7AAD positive or negative cells.


Supplementary Figure 7. CHD4 silencing does not affect normal human MRC5 or myoblast cells. Representative bright-field images of MRC5 and myoblast cells 72 hrs after induction of CHD4 silencing with doxycycline (Dox) in indicated cell lines and uninduced control cells, magnification 100x.


Supplementary Figure 8. Interaction of PAX3-FOXO1 with NuRD complex components persists after FOXO1 silencing. (A) Western blots showing FOXO1 silencing efficiency and effect on PAX3-FOXO1 expression level after treatment of RH4 cells with indicated siRNAs blots showing FOXO1 silencing efficiency and effect on PAX3-FOXO1 expression level after treatment of RH4 cells with indicated siRNAs IPs and lysates from scrambled control and FOXO1 knockdown RH4 cells. PAX3-FOXO1 and FOXO1 were precipitated by the anti-FOXO1 antibody and uncoated beads served as negative control (ctrl).

PAX3-FOXO1 directly downregulated geneset shCHD4 rank ordered datase


PAX3-FOXO1 indirectly upregulated genese shCHD4 rank ordered dataset


PAX3-FOXO1 indirectly downregulated geneset shCHD4 rank ordered dataset


Supplementary Figure 9. CHD4 depletion does not affect PAX3-FOXO1 indirectly affected or directly repressed genes. Gene se enrichment analysis using CHD4 regulated genes in RH4 cells as the rank ordered data set and PAX3-FOXO1 targets as the geneset. Left panel: GSEA using 106 directly PAX3-FOXO1 downregulated genes as geneset (fold change> $1.7, \mathrm{p}<0.05$ ). Middle panel: GSEA using 144 indirectly upregulated PAX3-FOXO1 targets as geneset. (fold change> 2.0, p<0.05). Right panel: GSEA using the 191 indirectly downregulated PAX3-FOXO1 targets as geneset (fold change>, p<0.05). Normalized enrichment score (NES) and p-value are shown.


Supplementary Figure 10. CHD4 inhibition in RD cell xenografts. In vivo treatment of NOD/Scid mice engrafted with RD cells containing stably integrated doxycycline inducible shCHD4\#1 or shscr expression vectors. Mice bearing palpable tumors were treated intraperitonealy for two days with either vehicle control or doxycycline at a dose of $53.3 \mathrm{mg} / \mathrm{kg}$. Additionally starting from the first day of treatment mice were fed with doxycycline supplemented food or control food. (A) Left panel: Absolute tumor volumes of xenografts upon treatment. Absolute tumor volume was measured by caliper. ShCHD4 groups consisted of 5 mice and shscr groups consisted of 4 mice. Right panel: CHD4 mRNA levels in one representative tumor of each group after 4 days of doxycycline treatment. CHD4 expression level of the treated tumor was normalized to the corresponding untreated tumor. (B) Immunohistochemical stainings of tumors with indicated antibodies. Tumors were excised four days after doxycycline treatment start.


Supplementary Figure 11. CHD4 is expressed in human FP-RMS and FN-RMS tumors. (A) Patient-derived tissue microarray immunohistochemically stained for CHD4 expression, FP-RMS $(\mathrm{n}=57)$ and FN-RMS $(\mathrm{n}=195)$. Per patient only strongest staining tumor biopsy core was considered. Patients were grouped according the following semiquantitative scoring system into negative, moderate or strong CHD4 expression. The intensity of staining was classified as weak (1) or strong (2), and the staining pattern was classified as negative (0:0\%), sporadic (1:1\% to $25 \%$ ), focal ( $2: 26 \%$ to $50 \%$ ) or diffuse ( $3: \geq 51 \%$ ). An overall expression score was calculated by multiplying the intensity and positivity scores: 0 (negative, aRMS=2, eRMS=10), 1-3 (moderate, aRMS=33, eRMS=73), 4-6 (strong, aRMS=22, eRMS=112). (B) Representative FPRMS and FN-RMS tumor core of CHD4 strong expression cohorts.

